ALPHA–2–MACROGLOBULIN COMPLEXES WITH IGG ANTIBODIES, PLASMIN, AND THEIR INTERRELATION WITH OTHER FACTORS OF HUMORAL IMMUNITY DURING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS

Abstract. Human alpha–2–macroglobulin (α2–MG) acts as a broad–spectrum cytokine and proteasebinding protein, and it represents an evolutionarily conserved arm of innate immune system. Meanwhile, previous studies have shown that rheumatoid arthritis (RA) development may cause alterations in α2–MG conformation and lessen its ability to bind and utilise regulatory substances. We investigated serum contents of α2–MG–IgG and α2–MG–plasmin complexes, as well as total concentrations ofα2–MG, plasmin (Pl), IgG, IL–6, IL–1β, TNFα and Rf–IgM, in order to evaluate the levels of anti–α2–MG antibody production in sera of patients with different degrees of RA activity and some interrelations of preformed immune complex with some other substances implicated in RA development. Serum samples were obtained in acute phase of RA, before the treatment was started. We have revealed significantly increased levels of α2–MG–IgG complex in the groups with severe RA, accompanied by increase in total IgG levels, without significant changes in total α2–MG concentrations. We have also demonstrated that increased levels of Pl–α2–MG complex did correspond to the severity of disease, and showed statistically high correlation with α2–MG–IgG levels. We have found a significant increase of IL–1β, IL–6, TNFα and Rf–IgM in RA, in absence of significant correlations with α2–MG–IgG contents. The results obtained allow us to suggest that abundant accumulation of serum antibodies to α2–MG or Pl–α2–MG complex during inflammation in the people with innate α2–MG deficiency, followed by increased levels of proinflammatory cytokines, may provoke a cascade–like development of RA. Serum levels of α2–MG may serve as prognostic marker in RA. (Med. Immunol., 2005, vol.7, № 5–6, pp. 557–562)

1. Зорина В.Н., Зорина Р.М., Зорин Н.А., Левченко В.Г., Горлина Н.К., Архипова С.В. Антигенспецифический способ определения иммунных комплексов белков семейства макроглобулинов с иммуноглобулином класса G в биологических жидкостях //Патент РФ №2209435 – Официальный бюллетень Российского агентства по патентам и товарным знакам «Изобретения. Полезные модели» – 2003. – №21. – Ч.3. — С.598.

2. Зорин Н.А., Жабин С.Г., Лыкова О.Ф., Зорина Р.М., Горин В.С., Белогорлова Т.И., Чирикова Т.С., Краюшкина Н.А. Белки плазмы и сыворотки крови доноров // Клин. Лаб. Диагн. – 1992. — №9–10. – С.1315.

3. Зорин Н.А., Зорина В.Н., Зорина Р.М., Левченко В.Г. Универсальный регулятор – α2–макроглобулин (Обзор литературы)// Клин. Лаб. Диагн. – 2004. – №11. – С.18–22.

4. Зорин Н.А., Зорина В.Н., Зорина Р.М. Универсальный модулятор цитокинов α2–макроглобулин // Иммунология – 2004. — №5. — С.302–304.

5. Зорина В.Н., Зорина Р.М., Левченко В.Г., Воронина Е.А, Зорин Н.А. Концентрация комплексов макроглобулин – IgG, как возможный критерий для прогнозирования гестоза и оценки степени его тяжести// Клин. Лаб. Диагн. – 2001. — №8. – С.48–49.

6. Насонова В.А., Астапенко М.Г. Клиническая ревматология. Руководство. – М: Медицина, 1989. – 592 с.

7. Armstrong P.B., Quigley J.P. α2–macroglobulin: an evolutionarily conserved arm of the innate immune system// Dev. Comp. Immunol. – 1999. – Vol.23. – P.375–390.

8. Birkenmeier G. Targetting the proteinase inhibitor and immune modulatory function of human α 2–Macroglobulin// Mod. Asp. Immunol. – 2001. – Vol.2. – P.32–36.

9. Blass S., Engel J.M., Burmester G.R. The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences// Zeitschrift Fur Rheumatologie – 2001. — Vol.60. – P.1–16.

10. Dominguez M., Cacoub P., Garcia de la Torre I., Piette T.J., Salazar Paramo M., Godeau P., Anglees Cano E. Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases // J. Rheumatol. – 2001. – Vol.28. – P.302–308.

11. Kramer P.R., Kramer S.F., Guan G. 17 betaestradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocytederived macrophages // Arthritis Rheum. – 2004. – Vol.50. – P.1967–1975.

12. Misra U.K., Gonzalez–Gronow M., Gawdi G., Pizzo S.V. Upregulation of the α2–macroglobulin signaling receptor on rheumatoid synovial fibroblasts// J. Biol. Chem. – 1997. – Vol.272. – P. 497–502.

13. Petersen C.M. α2–macroglobulin and pregnancy zone protein. Serum levels, α2–macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology// Danish Med. Bull. – 1993. – Vol.40. – P.409–446.

14. Stief T.W., Kropf J., Kretschmer V., Doss M.O., Fareed J. Singlet oxygen ((1)O2) inactivates plasmatic free and complexed α2–macroglobulin// Thromb. Res. – 2000. – Vol.98. – P.541–547.

15. Tchetverikov I., Verzijl N., Huizinga T.W., TeKoppele J.M., Hanemaaijer R., DeGroot J. Active MMPs captured by α2–macroglobulin as a marker of disease activity in rheumatoid arthritis // Clin. Exp. Rheumatol. – 2003. – Vol.21. – P.711–718.

16. Walsmith J., Roubenoff R. Cachexia in rheumatoid arthritis// Int. J. Cardiol. – 2002. – Vol.85. – P.89–99.

17. Wu S.M., Boyer C.M., Pizzo S.V. The binding of receptorrecognized α2–macroglobulin to the low density lipoprotein receptorrelated protein and the α2M signaling receptor is decoupled by oxidation // J. Biol. Chem. – 1997. – Vol.272. – P.20627–20635.

18. Wu S. M., Pizzo S.V. Mechanism of hypochloritemediated inactivation of proteinase inhibition by α2macroglobulin // Biochemistry – 1999. – Vol.38. – P.13983–13990.

19. Wu S.M., Pizzo S.V. Alpha(2)–Macroglobulin from rheumatoid arthritis synovial fluid: functional analysis defines a role for oxidation in inflammation // Arch. Biochem. Biophys. – 2001. – Vol.391. – P. 119–126.

20. Zapico I., Coto E., Rodriguez A., Alvarez C., Torre J.C., Alvarez V.A. A DNA polymorphysm at the α2–macroglobulin gene is associated with the severity of rheumatoid arthritis // J. Rheumatol. – 2000 – Vol.27. – P. 2308–2311.